Month: December 2020

                               Déclaration du nombre total de droits de vote et du nombre d’actions composant le capitalau 30 novembre 2020CLICHY, – 03 Décembre, 2020Article L 233-8-II du code de Commerce et article 223-16 du Règlement général de l’Autorité des Marchés Financiers.Au 30 novembre 2020, le capital social de SOCIÉTÉ BIC est composé de 45 532 240 actions, représentant :66 966 176 droits de vote,66 419 073 droits de vote nets des actions privées de droits de voteÀ PROPOS DE BICBIC est un des leaders mondiaux des articles de papeterie, des briquets et des rasoirs. Depuis plus de 75 ans, l’entreprise fabrique des produits de grande qualité accessibles à tous, partout dans le monde. Cette vocation a permis au Groupe de faire de sa marque, enregistrée dans le monde entier, l’une des plus reconnues. Aujourd’hui, les produits BIC®...

31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patientsMedian duration of response = 8.13 monthsROCKVILLE, MD, Dec. 06, 2020 (GLOBE NEWSWIRE) —  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a single-arm, registrational study of flotetuzumab, an investigational, bispecific CD123 × CD3 DART® molecule, in patients with primary induction failure (PIF) and early relapsed (less than six months, or ER6) acute myeloid leukemia (AML). The data were presented at the 62nd Annual Meeting of the American Society of Hematology (ASH) taking place December 5-8, 2020.In the open label study of flotetuzumab, 44 AML patients had disease classified...

Results Demonstrate Ability of AlloCAR T™ Therapy to Selectively Kill CD70 Expressing Leukemic CellsCoupled with Previous Findings in Renal Cell Carcinoma (RCC), Results Highlight the Potential of ALLO-316 to Treat Both Hematologic Malignancies and Solid TumorsInvestigational New Drug (IND) Application for ALLO-316 Cleared by U.S. Food and Drug Administration (FDA); Phase 1 Trial in RCC to Start in 2021SOUTH SAN FRANCISCO, Calif., Dec. 06, 2020 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced preclinical findings of ALLO-316, an AlloCAR T™ therapy targeting CD70, in models of acute myeloid leukemia (AML). Data were presented in a poster session today at the 62nd Annual Meeting of...

SEATTLE, Dec. 06, 2020 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new real-world data highlighting the clinical utility of Adaptive’s next-generation sequencing (NGS) clonoSEQ® Assay to assess minimal residual disease (MRD) in patients with multiple myeloma. The data are being presented at the American Society of Hematology (ASH) 62nd Annual Meeting and Exposition, held virtually December 5-8. Additional study results demonstrating the impact of Adaptive’s clonoSEQ Assay in chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) and mantle cell lymphoma (MCL) are also being presented at the meeting in 45 other abstracts.MRD...

—Data presented at the 62nd American Society of Hematology Annual Meeting—RESEARCH TRIANGLE PARK, N.C., Dec. 06, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that preclinical data on BCX9930, an oral Factor D inhibitor under development as monotherapy for paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases, showed complete in vitro blockade of both hemolysis of PNH erythrocytes and accumulation of C3 fragments on PNH erythrocytes, indicating that BCX9930 monotherapy has the potential to inhibit both intravascular and extravascular hemolysis.In the study, BCX9930 was highly specific for the alternative pathway and, after oral dosing of BCX9930 in primates, alternative pathway activity was completely suppressed.The data were presented at the 62nd American Society...

Updated interim data from CPI-818’s phase 1/1b clinical trial provide evidence supporting its potential as a treatment for T cell lymphomasNew pre-clinical data provide evidence of CPI-818 potential as a treatment for autoimmune lymphoproliferative syndrome (ALPS)BURLINGAME, Calif., Dec. 06, 2020 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new data on CPI-818, the Company’s ITK inhibitor, were presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place as an all-virtual event from December 5-8, 2020. The data include a poster presentation covering updated data from the Phase 1/1b clinical trial for T cell lymphoma and an oral presentation covering pre-clinical data demonstrating its potential...

Two Inclacumab Pivotal Phase 3 Clinical Trials Expected to Begin in First Half of 2021GBT021601 – Potent Next–Generation Hemoglobin S Polymerization Inhibitor Shown to be Highly Effective in SCD Animal ModelsSOUTH SAN FRANCISCO, Calif., Dec. 06, 2020 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced new preclinical data on its sickle cell disease (SCD) pipeline therapies – inclacumab, a novel P-selectin inhibitor in development to reduce the frequency of vaso-occlusive crises (VOCs) in patients with SCD, and GBT021601, a next-generation hemoglobin S (HbS) polymerization inhibitor. These data are being presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.“In pursuit of our mission to transform the treatment of and care for people living with...

Final 72-Week Analyses of Phase 3 HOPE Study Demonstrate Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health StatusReal-World Experience Study Results Consistent with HOPE Study and Show Improved Patient Health StatusSOUTH SAN FRANCISCO, Calif., Dec. 06, 2020 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced new data from the 72-week analyses of the Phase 3 HOPE Study of Oxbryta® (voxelotor) tablets in patients with sickle cell disease (SCD). These data, as well as new findings from real-world experience studies of Oxbryta, are being presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.“We are pleased that the longer term, 72-week HOPE Study data are consistent with the previously reported 24-week primary analyses,...

Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million CellsDeepening of Response Observed with FT596 RetreatmentDuration of Response Comparable to FDA-approved Autologous CAR T-cell Therapy for Patients with Partial ResponseNo Observed Events of Any Grade of Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, or Graft-vs-Host DiseaseSAN DIEGO, Dec. 06, 2020 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today presented a patient case study from the Company’s Phase 1 clinical trial of FT596, its universal, off-the-shelf, CD19-targeted chimeric antigen receptor (CAR) natural killer (NK)...

Surplus for Swedish central government in November 2020Swedish central government payments resulted in a surplus of SEK 40.4 billion in November. The Debt Office’s forecast was a surplus of SEK 20.5 billion. The difference is due to lower disbursements and higher tax income than expected.The report Sweden’s Central Government Debt November 2020 was accidentally published prematurely on Sunday 6 December instead of Monday 7 December at 9:30 CET as scheduled. Due to this error, the Swedish National Debt Office is now publishing in advance the outcome of central government payments and the size of the central government debt for November 2020 in its entirety.The primary balance was SEK 20.4 billion higher than forecasted. Tax income were approximately SEK 7 billion higher than calculated. In addition, disbursements from a number of...